Adaptive Biotechnologies (NASDAQ: ADPT) Chief People Officer Francis Lo disposed of 30,593 shares of the company’s common stock on March 11, 2026, realizing proceeds of $430,749. The block of shares sold carried a weighted average sale price between $13.81 and $14.38 per share.
The sale was reported on a Form 4 filed with the Securities and Exchange Commission and was carried out pursuant to a Rule 10b5-1 trading plan that Lo adopted on September 15, 2025. Following this executed transaction, Lo directly holds 291,374 shares of Adaptive Biotechnologies and holds an additional 2,500 shares indirectly through a spouse.
At the time of reporting, Adaptive Biotechnologies was trading at $13.17, reflecting an 11% decline over the past week. Despite the recent pullback, the stock remains up 81% over the prior 12 months. Independent valuation analysis referenced in public commentary indicates the shares currently appear overvalued relative to a Fair Value estimate, placing the company among candidates for a Most Overvalued stocks list.
Earnings and analyst response
Adaptive Biotechnologies released its fourth-quarter 2025 financial results that outperformed consensus estimates. The company posted adjusted earnings per share of -$0.09, representing a 50% positive surprise versus an expected -$0.18. Revenue for the quarter reached $71.7 million, topping the projected $59.33 million and exceeding estimates by 20.85%.
Analysts reacted to the stronger-than-expected performance. BTIG raised its price target to $22.00, citing robust expansion in the company’s Minimal Residual Disease (MRD) business, which grew 54% year-over-year in the fourth quarter and produced 46% revenue growth for the full year. TD Cowen adjusted its target to $21.00 following the quarterly results. Piper Sandler maintained an Overweight rating, highlighting Adaptive’s solid positioning in the MRD space and forecasting more than 30% volume growth for the clonoSEQ product.
Context for investors
The timing of the insider sale was governed by a pre-established trading arrangement under Rule 10b5-1, a mechanism executives commonly use to manage trades in advance of market-moving events. While the transaction is material in value, the company’s recent operational results and the subsequent analyst attention underscore ongoing interest in Adaptive’s MRD franchise and revenue trajectory.
For investors seeking deeper analysis of Adaptive Biotechnologies’ valuation and financials, a Pro Research Report covering this company and more than 1,400 other U.S. equities is available through a named research platform.
Disclosure: